#Switzerland #Pilatus Biosciences #PLT012 #Epalinges #SITC 2025

Introduction

Pilatus Biosciences is making waves in the field of immunotherapy as it prepares for the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, scheduled from November 5-9, 2025, in National Harbor, Maryland. The company will present new and promising preclinical data focusing on its lead product candidate, PLT012, a pioneering therapy aimed at addressing liver and gastrointestinal cancers.

About PLT012

PLT012 represents a new class of monoclonal antibodies specifically designed to inhibit the CD36 receptor involved in lipid uptake. This mechanism is crucial as it addresses immunosuppressive processes within the tumor microenvironment. By effectively blocking CD36, PLT012 not only depletes cells that hinder immune responses, such as Tregs (regulatory T cells) and tumor-promoting macrophages, but also enhances the capacity of intratumoral NK (natural killer) cells and cytotoxic CD8+ T cells to fight cancer. Early studies indicate that PLT012 may work as a monotherapy with strong efficacy in liver cancer models. Furthermore, it shows promise as a companion therapy that increases the effectiveness of existing treatments, such as anti-PD-L1 therapies, especially in traditionally resistant 'cold' tumors and liver metastases.

Presentation Highlights at SITC 2025

The lead scientist at Pilatus, Dr. Yi-Ru Yu, will present key findings that suggest the dual action of PLT012. He states, "Our preclinical findings reveal that by reprogramming immune-metabolic pathways, PLT012 effectively suppresses Tregs while simultaneously bolstering CD8+ T-cell responses, particularly in lipid-rich tumors. This effective mechanism not only drives superior anti-tumor efficacy but also promotes lasting immunological memory to maintain tumor control and defend against return challenges." Dr. Raven Lin, the CEO of Pilatus, emphasized the significance of these findings within the context of their upcoming Phase I clinical trial, targeted to commence in Q1 2026.

SITC 2025 Presentation Details

The abstract of the poster presentation titled "PLT012: A Humanized CD36-Blocking Antibody Induces Durable Anti-Tumor Immunity via Immunometabolic Reprogramming" will be available on SITC's website on November 4, 2025. The key details of the presentation are summarized as follows:

• - Presenting Author: Yi-Ru Yu, Ph.D.
• - Presentation Date: Friday, November 7, 2025
• - Time: 12:15 PM – 1:45 PM EST
• - Poster Number: 1205

Conclusion

Pilatus Biosciences stands at the forefront of innovation in cancer treatment with PLT012, aiming not just to enhance anti-tumor responses but to also facilitate lasting immunity. With a favorable safety profile noted across species and a compelling rationale for its clinical application, PLT012 could significantly change the landscape of cancer therapeutics. For those interested in the latest advancements in the fight against cancer, Pilatus' presentation at SITC 2025 is a critical highlight.